[Lani]

1: J Clin Oncol. 2008 Sep 15. [Epub ahead of print]
PMID: 18794539 [PubMed - as supplied by publisheMetronomic Cyclophosphamide and Capecitabine Combined With
Bevacizumab in Advanced Breast Cancer.
Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano
E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri
E, Colleoni M.
Medical Senology Research Unit and Division of Medical Oncology, Department of
Medicine; Division of Hematology-Oncology, Department of Medicine; and Division
of Epidemiology and Biostatistics, European Institute of Oncology; Department of
Statistics, University of Milan-Bicocca, Milan, Italy; Molecular and Cellular Biology
Research, Sunnybrook Health Sciences Centre; Department of Medical Biophysics,
University of Toronto, Toronto, Ontario, Canada; and Oncology Institute of
Southern Switzerland, Bellinzona and Lugano, Switzerland.
PURPOSE: Metronomic chemotherapy has shown efficacy in patients
with metastatic breast cancer. When used in association with targeted
antiangiogenic drugs, it was more active than metronomic therapy
alone in preclinical and clinical studies. PATIENTS AND METHODS:
Patients with advanced breast cancer were candidates to receive
metronomic oral capecitabine (500 mg thrice daily) and
cyclophosphamide (50 mg daily) plus bevacizumab (10 mg/kg every 2
weeks). RESULTS: In 46 assessable patients, we observed one
complete response (CR; 2%), 21 partial responses (PR; 46%), 19
patients (41%) with stable disease (SD), and five patients (11%) with
progressive disease, for an overall response rate of 48% (95% CI,
33% to 63%). Additional long-term disease stabilization (SD >/= 24
weeks) occurred in eight patients, for an overall clinical benefit (CR +
PR + SD >/= 24 weeks) of 68% (95% CI, 51% to 81%). Median
time to progression was 42 weeks (95% CI, 26 to 72 weeks).
Toxicity was generally mild. Grade 3 or 4 nonhematologic adverse
effects included hypertension (n = 8), transaminitis (n = 2), and
nausea/vomiting (n = 2). Higher baseline circulating endothelial cells
(CECs) were correlated with overall response (P = .02), clinical benefit
(P = .01), and improved progression-free survival (P = .04).
CONCLUSION: Treatment with metronomic capecitabine and
cyclophosphamide in combination with bevacizumab was effective in
advanced breast cancer and was minimally toxic. The number of
baseline CECs significantly correlated with response and outcome,
therefore supporting further studies on this surrogate marker for the
selection of patients to be candidates for antiangiogenic treatments.


This was for her2- bc (for her2+ they combined metronomic w herceptin)

Virtually all trials want normal liver functions as they do not want to cause liver failure/unacceptable toxicity caused by their "experimental combination"

Let's hope you mom's LFT problems were due to a virus or other transient, correctible cause. This happened to my dad about three weeks ago. His LFTs were 100 times normal and it was assumed it was due to one of his two cancers (one of which is already known to have metastasized to his liver). But two weeks later his LFTs were normal --his doctor ordered antibody titers for cytomegalovirus before going on vacation. It is unclear to me if they were ever done, or how they came out, but as my fathers LFTs went back to normal, it became a moot point.